BIOMAT Database Logo BIOMAT Database Logo

Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. 1993

V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Istituto Semeiotica Medica, Università Cattolica, Rome, Italy.

The case of an adult patient with moderately severe protein C deficiency (antigen 16%, activity 12%) is reported. Both parents had protein C levels compatible with heterozygous deficiency. Unlike other reported cases of severe protein C deficiency in adults, the onset of thrombotic symptoms occurred at 1 month of age; however, a symptom-free period until age 17 followed. Replacement therapy with a monoclonal antibody purified protein C concentrate was carried out during the initiation of oral anticoagulation after a course of i.v. heparin for deep vein thrombosis. The administration of the concentrate allowed maintenance of protein C above 50% until a stable therapeutic anticoagulation level could be obtained. This was reached within a short time, thus allowing safe administration of a loading dose of warfarin. We conclude that this approach to the prevention of skin necrosis seems more rapid and safer than previous schedules of oral anticoagulation in protein C-deficient patients.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010375 Pedigree The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition. Family Tree,Genealogical Tree,Genealogic Tree,Genetic Identity,Identity, Genetic,Family Trees,Genealogic Trees,Genealogical Trees,Genetic Identities,Identities, Genetic,Tree, Family,Tree, Genealogic,Tree, Genealogical,Trees, Family,Trees, Genealogic,Trees, Genealogical
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011486 Protein C A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin

Related Publications

V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency.
January 1995, Seminars in thrombosis and hemostasis,
V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Successful protein C concentrate administration during initiation of oral anticoagulation in adult patients with severe congenital protein C deficiency: report of two cases.
January 2008, Pathophysiology of haemostasis and thrombosis,
V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Long-term management of homozygous protein C deficiency: replacement therapy with subcutaneous purified protein C concentrate.
June 1999, Thrombosis and haemostasis,
V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Treatment of inherited protein C deficiency by replacement therapy with the French purified plasma-derived protein C concentrate (PROTEXEL).
October 2007, Vox sanguinis,
V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate.
January 1996, European journal of pediatrics,
V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate.
November 1991, The New England journal of medicine,
V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulant treatment.
February 1984, Thrombosis and haemostasis,
V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Protein C survival during replacement therapy in homozygous protein C deficiency.
September 1992, American journal of hematology,
V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Replacement therapy for a homozygous protein C deficiency-state using a concentrate of human protein C and S.
December 1988, British journal of haematology,
V De Stefano, and S Mastrangelo, and H P Schwarz, and P Pola, and R Flore, and B Bizzi, and G Leone
Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency.
August 1993, Blood,
Copied contents to your clipboard!